NeoGenomics Posts Mixed 2025 Results Amid Strategic Shifts
Event summary
- NeoGenomics reported 11% Q4 revenue growth to $190M and 10% full-year growth to $727M
- Net loss widened 37% to $108M for 2025 despite adjusted EBITDA growth of 9% to $43M
- NGS testing grew 23% in Q4, outpacing market growth rates
- Company anticipates modest 2026 revenue contribution from RaDaR ST MRD assay launch
- 2026 guidance projects 9-10% revenue growth with net loss reduction of 42-54%
The big picture
NeoGenomics' mixed 2025 results reflect the tension between revenue growth from higher-value tests and persistent net losses. The company's strategic focus on precision medicine and community channel leadership positions it well in the evolving oncology diagnostics market, but execution on new product launches like RaDaR ST will be critical for long-term success. The $727M revenue base provides a solid foundation for expansion in the growing molecular residual disease monitoring space.
What we're watching
- Market Positioning
- How NeoGenomics will leverage its 80% community channel leadership to drive long-term MRD assay adoption
- Financial Performance
- Whether the company can sustain adjusted EBITDA growth while managing widening net losses
- Product Innovation
- The pace at which RaDaR ST MRD assay gains traction in the $20B molecular residual disease monitoring market
Related topics